May 21, 2018 / 12:18 PM / 3 months ago

BRIEF-Precigen Announces First Patient Dosed In Phase 1 Clinical Study Of INXN-4001

May 21 (Reuters) - Intrexon Corp:

* PRECIGEN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL STUDY OF INXN-4001 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below